Xinyuan Liu

Xinyuan Liu

Auto-generated profile, based on publicly available information

Xinyuan Liu

Pancreas Cancer Research Lab, Department of Clinical Science, Intervention and Technology, (CLINTEC), Karolinska Institutet, Huddinge SE 141 86, Sweden

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Translational Oncology
Verified
Journal Article
Open access
XLXinyuan Liu
Xinyuan Liu
BGBeate Gündel
Beate Gündel
XLXidan Li
Xidan Li
JLJianping Liu
Jianping Liu
AWAnthony Wright
Anthony Wright
RHRainer Heuchel
Rainer Heuchel
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, partly due to the dense desmoplasia and a lack of suitable model systems to study. In the present work, we developed a 3D heterospecies spheroid model to study the microenvironmental interactions between tumor cells and stellate cells which can also be employed to test therapeutic regimens. We set up monospheroids and heterospheroids made up from murine pancreatic stellate cells (mPSCs) and human PDAC cells (Panc1), which allowed for direct isolation of mRNA from a mixed cell population followed by an in silico separation of the RNA-seq reads. Global transcript level changes for cells in heterospheroids versus monospheroids were calculated, followed by gene set enrichment analysis and molecular subtype analysis. We observed an apparent shift of Panc1 from the classical to the squamous/basal-like phenotype upon co-culture with mPSCs. Moreover, mPSCs acquired a different cancer-associated fibroblast-related phenotype upon co-culture with Panc1. We analyzed the tumor cell-specific chemosensitivities towards gemcitabine, paclitaxel and SN38 and compared these to published pharmacotranscriptomic signatures. In conclusion, our heterospecies spheroid model reflected key aspects of PDAC and facilitated the study of intercellular interactions between tumor and stroma while additionally proving to be a good model for studying therapeutic responses.

14 August 2008 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
CSChangqing Su
Changqing Su
HCHui Cao
Hui Cao
STShuping Tan
Shuping Tan
YHYao Huang
Yao Huang
XJXiaoyuan Jia
Xiaoyuan Jia
QQQian Qijun
Qian Qijun
Conditionally replicating adenovirus (CRAd) has demonstrated to be safe in clinical studies. We generated a triple-regulated p53-armed CRAd, SG600-p53, in which the partially deleted E1a and E1b genes are regulated under the human telomerase reverse transcriptase promoter and the hypoxia response element. SG600-p53 was proven to be effective both in vitro and in vivo. In this study, the preclinical safety profiles of SG600-p53 in animal models were investigated. SG600-p53 had no adverse effects on mouse behavioral and nervous systems at 1.0 × 1011 viral particles (VP)/kg, 2.0 × 1011 VP/kg and 4.0 × 1011 VP/kg doses, and on cat cardiovascular and respiratory systems at 2.0 × 1010 VP/kg, 4.0 × 1010 VP/kg, and 8.0 × 1010 VP/kg doses. In acute toxicity test in mice, the maximum tolerated dose (2.5 × 1013 VP/kg) induced cachexia, decreased activity, and eye closure in 9/20 mice which could be self-resolved within 30 min. Sensitized by five repeated ip injections at 1.0 × 1010 VP/kg each ip and excitated by one iv injection at 1.0 × 1011 VP/kg, guinea pigs did not show any sign of systemic anaphylaxis. In repeat-dose toxicological studies, the no-observable-adverse-effect levels of SG600-p53 in rats (1.0 × 1011 VP/kg) and cynomolgus monkeys (5.0 × 1011 VP/kg) were 12-fold and 60-fold of the proposed clinical dose, respectively. Intramuscular injections of SG600-p53 in cynomolgus monkeys caused inflammation at injection sites, which was alleviative at the end of observation period. The anti-virus antibody was produced in animal sera and decreased gradually 4 weeks later. No histopathological changes were found by bone marrow examination. Our data in different animal models suggest that SG600-p53 is a safe antitumor therapeutic agent.

1 May 2004 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
ZZZilai Zhang
Zilai Zhang
JWJinhui Wang
Jinhui Wang
WZWeiguo Zou
Weiguo Zou
BLBinghua Li
Binghua Li
ZPZifei Pei
Zifei Pei
XLXinyuan Liu
Xinyuan Liu
Zilai Zhang,1 Jinhui Wang,1 Weiguo Zou,1 Binghua Li,1 Zifei Pei,1 Jinfa Gu,1 Cheng Qian,2 Xinyuan Liu.1 1Institute of Biochemistry and Cell Biology,Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, Shanghai, China; 2Medicine, Medical School, University of Navarra, Pamplona, Spain. Armed oncolytic adenoviruses represent an appealing tumor treatment. In this paper, considing that angiogenesis play an important role in tumor growth, the antiangiogenic gene, sflt-1(1-3) (the first three extracellular domain of hVEGF receptor) was inserted into ZD55 (an E1B55-kD deleted oncolytic adenovirus previously constructed in our lab) to form ZD55-sflt-1. ZD55-sflt-1 could specifically induce cytopathic effect in tumor cells in vitro. The expression of sFLT-1 from ZD55-sflt-1 was much higher than that of replication–deficient Ad-sflt-1, which contributed to its stronger inhibitory effect of VEGF-induced HUVEC proliferation (35.4386% of control). Furthermore, a marked reduction of tumor growth was observed in ZD55-sflt-1-treated nude mice with subcutaneous human SW620 colon tumor. Its efficacy directly corrected with a decrease in microvessel density and an increase in apoptosis of tumor cells. A much more efficient antitumoral effect was obtained when ZD55-sflt-1 was combined with ZD55-trail (another oncolytic adenovirus engineered to express the tumor necrosis factor-related apoptosis-inducing ligand), which resulted in 57.14% complete tumor regression and 71.43% prolonged survival of mice. These results indicate that ZD55-sflt-1, which combines the advantages of oncolytic adenovirus and the antiangiogenic gene system, can result in a striking improvement in treatment efficacy, and is suitable for synergistic therapy with other agents.

1 May 2005 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
LZLili Zhao
Lili Zhao
JGJinfa Gu
Jinfa Gu
ADAi-wen Dong
Ai-wen Dong
YZYanhong Zhang
Yanhong Zhang
LHLingfeng He
Lingfeng He
XLXinyuan Liu
Xinyuan Liu
Li-li Zhao,1,2 Jin-fa Gu,2 Ai-wen Dong,2 Yan-hong Zhang,2 Ling-feng He,2 Jin-he Zhang,2 Yi-gang Wang,1 Zi-lai Zhang,2 Qi-jun Qian,1,4 Cheng Qian,1,3 Xin-yuan Liu,1,2